Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies

Subjects

Abstract

In 2007 the WMDA responded to the publication of two manuscripts suggesting a causal link between G-CSF and myeloid malignancies in healthy donors by convening an international symposium to examine this issue. At the time, registries reviewed the long-term follow-up of their healthy donors, which suggested no excess of leukaemia in PBSC donors compared with BM donors. Although the evidence for an increased risk of malignancy in healthy donors was felt to be weak, it could not be excluded. The WMDA, therefore, issued a statement, to be included in all donor consent forms, stating that it was unknown whether G-CSF increased or decreased the risk of later developing cancer. In 2012, with 5 years of additional donor follow-up and the results of several genetic studies now available, the clinical working group of the WMDA again reviewed the data. On the basis of an assessment of a continuing lack of evidence for an increased risk of malignancy in donors receiving G-CSF, the WMDA has re-issued a more reassuring statement. The revised statement was circulated to all WMDA member registries in late 2012 to replace the existing statement in consent forms, which now conclusively states that, ‘Studies following large numbers of unrelated donors have shown that the risk of developing cancer within several years after the use of G-CSF is not increased compared with donors not receiving G-CSF. Herein we review the evidence on which this statement is based.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014; 49: 744–750.

    Article  PubMed  PubMed Central  Google Scholar 

  2. de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994; 84: 3885–3894.

    CAS  PubMed  Google Scholar 

  3. Anderlini P, Champlin RE . Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111: 1767–1772.

    Article  CAS  PubMed  Google Scholar 

  4. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642–650.

    Article  CAS  PubMed  Google Scholar 

  5. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L . Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122–130.

    Article  CAS  PubMed  Google Scholar 

  6. Pamphilon D, Mackinnon S, Nacheva E, Russell N, Wilson K, Clay M et al. The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant 2006; 38: 699–700.

    Article  CAS  PubMed  Google Scholar 

  7. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107: 4628–4635.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 2009; 94: 712–719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Donadieu J, Leblanc T, Bader Meunier B, Barkaoui M, Fenneteau O, Bertrand Y et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005; 90: 45–53.

    PubMed  Google Scholar 

  10. Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109: 2794–2796.

    Article  CAS  PubMed  Google Scholar 

  11. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002; 100: 786–790.

    Article  CAS  PubMed  Google Scholar 

  12. Confer DL, Miller JP . Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77–78 author reply 79-80.

    Article  PubMed  Google Scholar 

  13. Goldman JM, Madrigal JA, Pamphilon D . Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651–652.

    Article  CAS  PubMed  Google Scholar 

  14. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604–3611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood 2013; 121: 197–206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Miller JP, Perry EH, Price TH, Bolan CD Jr, Karanes C, Boyd TM et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14: 29–36.

    Article  PubMed  Google Scholar 

  17. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94–101.

    Article  PubMed  Google Scholar 

  18. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757–3763.

    Article  PubMed  Google Scholar 

  19. Avalos BR, Lazaryan A, Copelan EA . Can G-CSF cause leukemia in hematopoietic stem cell donors? Biol Blood Marrow Transplant 2011; 17: 1739–1746.

    Article  CAS  PubMed  Google Scholar 

  20. Storek J, Dawson MA, Maloney DG . Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood 2000; 95: 2993–2994.

    CAS  PubMed  Google Scholar 

  21. Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D et al. Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors. Transfusion 2010; 50: 2676–2685.

    Article  PubMed  Google Scholar 

  22. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.

    Article  CAS  PubMed  Google Scholar 

  23. Tassi C, Tazzari PL, Bonifazi F, Giudice V, Nannetti A, Ricci F et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005; 36: 289–294.

    Article  CAS  PubMed  Google Scholar 

  24. Quillen K, Byrne P, Yau YY, Leitman SF . Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion 2009; 49: 513–518.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31–34.

    Article  CAS  PubMed  Google Scholar 

  26. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R . Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 2003; 73: 33–36.

    Article  CAS  PubMed  Google Scholar 

  27. Hirsch B, Oseth L, Cain M, Trader E, Pulkrabek S, Lindgren B et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118: 2602–2608.

    Article  CAS  PubMed  Google Scholar 

  28. Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D et al. G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division. Blood 2010; 115: 910–911.

    Article  CAS  PubMed  Google Scholar 

  29. Olnes MJ, Poon A, Miranda SJ, Pfannes L, Tucker Z, Loeliger K et al. Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors. Transfusion 2012; 52: 537–541.

    Article  CAS  PubMed  Google Scholar 

  30. Graf L, Heimfeld S, Torok-Storb B . Comparison of gene expression in CD34+ cells from bone marrow and G-CSF-mobilized peripheral blood by high-density oligonucleotide array analysis. Biol Blood Marrow Transplant 2001; 7: 486–494.

    Article  CAS  PubMed  Google Scholar 

  31. Baez A, Martin-Antonio B, Piruat JI, Prats C, Alvarez-Laderas I, Barbado MV et al. Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors. Haematologica 2014; 99: 243–251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A . Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors. Acta Haematol 2007; 117: 68–73.

    Article  CAS  PubMed  Google Scholar 

  33. Hernandez JM, Castilla C, Gutierrez NC, Isidro IM, Delgado M, de las Rivas J et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19: 1088–1091.

    Article  CAS  PubMed  Google Scholar 

  34. Hasenclever D, Sextro M . Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17: S28–S30.

    PubMed  Google Scholar 

  35. Pulsipher MA, Chitphakdithai P, Logan BR, Navarro WH, Levine JE, Miller JP et al. Lower risk of serious adverse events and no increased risk of cancer after PBSC versus bone marrow donation. Blood 2014; 123: 3655–3663.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Holig K . G-CSF in Healthy Allogeneic Stem Cell Donors. Transfus Med Hemother 2013; 40: 225–235.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Schmidt AH, Mengling T, Pingel J, Rall G, Ehninger G . Follow-up of 12,559 Unrelated Donors of Peripheral Blood Stem Cells or Bone Marrow. Blood (ASH Annual Meeting Abstracts) 2010; 116 Abstract 365.

  38. Wiersum-Osselton JC, van Walraven SM, Bank I, Lenselink AM, Fibbe WE, van der Bom JG et al. Clinical outcomes after peripheral blood stem cell donation by related donors: a Dutch single-center cohort study. Transfusion 2013; 53: 96–103.

    Article  PubMed  Google Scholar 

  39. de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735–740.

    Article  CAS  PubMed  Google Scholar 

  40. Mueller MM, Bialleck H, Bomke B, Brauninger S, Varga C, Seidl C et al. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sang 2013; 104: 46–54.

    Article  CAS  PubMed  Google Scholar 

  41. Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S et al. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transplant 2014; 49: 195–200.

    Article  CAS  PubMed  Google Scholar 

  42. Jeger A, Favre G, Lutz JM, Stern M, Usel M, Rovo A et al. Tumor incidence in related hematopoietic stem cell donors. Bone Marrow Transplant 2011; 46: 1240–1244.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B E Shaw.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shaw, B., Confer, D., Hwang, W. et al. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplant 50, 334–340 (2015). https://doi.org/10.1038/bmt.2014.278

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.278

Search

Quick links